This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Bioavailability Study of Fixed Dose Combination (FDC) Formulations of Dapagliflozin and Metformin XR Versus Individual Component Coadministered to Healthy Subjects in a Fasted State

This study has been completed.
Bristol-Myers Squibb
Information provided by (Responsible Party):
AstraZeneca Identifier:
First received: October 26, 2009
Last updated: October 14, 2016
Last verified: October 2016
To assess the relative bioavailability of dapagliflozin and metformin from the two FDC formulations, comprised of 10 mg dapagliflozin and 1000 mg metformin XR, relative to coadministration of a dapagliflozin 10 mg tablet and 2 x 500 mg Glucophage® XR tablets, in healthy subjects in a fasted state.

Condition Intervention Phase
Type 2 Diabetes Mellitus (T2DM) Drug: Dapagliflozin Drug: Metformin XR Drug: Glucophage Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Official Title: Bioavailability Study of Two Prototype Fixed Dose Combination (FDC) Formulations of 10 mg Dapagliflozin and 1000 mg Metformin Extended Release (XR) Tablet Relative to Dapagliflozin 10 mg Tablet and Glucophage® XR 2 X 500 mg Tablets Coadministered to Healthy Subjects in a Fasted State

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Blood samples to measure the pharmacokinetic parameters Cmax and AUC for the combination products versus each investigational product alone [ Time Frame: 48 hours post-dose ]

Secondary Outcome Measures:
  • Safety and tolerability measures (adverse events, physical exams, vital signs, ECGs, and clinical laboratory assessments) [ Time Frame: 15 timepoints in 48 hours time interval ]

Enrollment: 15
Study Start Date: November 2009
Study Completion Date: January 2010
Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
FDC of dapagliflozin/metformin XR Drug: Dapagliflozin
Tablets, Oral, 10 mg, Single Dose
Drug: Metformin XR
Tablets, Oral, 1000 mg, Single Dose
FDC of dapagliflozin/reduced mass metformin XR Drug: Dapagliflozin
Tablets, Oral, 10 mg, Single Dose
Drug: Metformin XR
Tablets, Oral, 1000 mg, Single Dose
dapagliflozin and Glucophage® XR Drug: Dapagliflozin
Tablets, Oral, 10 mg, Single Dose
Drug: Glucophage
Tablets, Oral, 1000 mg, Single Dose
Other Name: Glucophage™


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Men and women ages 18 to 45 inclusive
  • Healthy subjects as determined by no clinically significant deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations
  • Body Mass Index (BMI) of 18 to 32 kg/m2, inclusive. BMI = weight (kg)/ [height (m)]2

Exclusion Criteria:

  • WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 8 weeks after the last dose of investigational product
  • Any significant acute or chronic medical illness
  • Current or recent (within 3 months) gastrointestinal disease
  • Any major surgery within 4 weeks of study drug administration
  • Glucosuria at screening
  • Abnormal liver functions tests (ALT, AST or total bilirubin > 10% above ULN)
  • Presence of edema on physical exam
  • History of diabetes mellitus
  • History of heart failure
  • History of renal insufficiency
  • History of chronic or recurrent UTI (defined as 3 occurrences per year) or UTI in the past 3 months
  • History of recurrent (defined as 3 occurrences per year) or recent vulvovaginal mycotic infections
  • Estimated creatinine clearance (ClCR) of < 80 mL/min using the Cockcroft Gault formula
  • History of allergy or intolerance to metformin or other similar agents
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01002807

United States, Texas
Ppd Development, Lp
Austin, Texas, United States, 78744
Sponsors and Collaborators
Bristol-Myers Squibb
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
  More Information

Additional Information:
Responsible Party: AstraZeneca Identifier: NCT01002807     History of Changes
Other Study ID Numbers: MB102-065
Study First Received: October 26, 2009
Last Updated: October 14, 2016

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Hypoglycemic Agents
Physiological Effects of Drugs processed this record on August 22, 2017